Boehringer Ingelheim to Present 29 Abstracts at the Annual American Thoracic Society International Conference

Boehringer Ingelheim Pharmaceuticals has announced that 29 abstracts from the company's respiratory portfolio will be presented at the 2015 American Thoracic Society (ATS) International Conference taking place 15–20 May in Denver, including data on investigational therapies for chronic obstructive pulmonary disease (COPD) and asthma, and on approved products for idiopathic pulmonary fibrosis (IPF) and COPD. Of the 29 accepted abstracts, 19 are on COPD, including key data from the Phase III TONADO trials of late-stage, investigational tiotropium/olodaterol Respimat.

"We are proud of our long-standing commitment to ongoing innovation in discovering and developing new treatments for serious lung conditions where there is an unmet need," said Danny McBryan, vice president, Clinical Development and Medical Affairs, Respiratory, Boehringer Ingelheim Pharmaceuticals, Inc. "We look forward to sharing our asthma, IPF and late-stage COPD data at ATS, as we continue to advance our portfolio of respiratory products."

In addition to the data presentations, Boehringer Ingelheim will provide attending healthcare professionals with several educational opportunities, including an Industry Theater Presentation, "The Role of Bronchodilators in the Long-Term Maintenance Treatment of Patients with COPD: A Review of the Data" (18 May at 11:45 am MT), and a dinner symposium featuring a panel of experts, "Selection of Long-Term Maintenance Therapy for Patients With COPD" (19 May at 6:30 pm MT).

Chronic Obstructive Pulmonary Disease (COPD) Presentations
Sub-analyses from the TONADO trials investigating the safety and efficacy of tiotropium/olodaterol Respimat in patients with COPD will be presented.

Tiotropium/olodaterol Respimat is an investigational maintenance treatment for patients with COPD and includes tiotropium, the active ingredient in Spiriva Respimat (tiotropium bromide) Inhalation Spray and Spiriva HandiHaler (tiotropium bromide inhalation powder), combined with olodaterol. Tiotropium/olodaterol Respimat is not currently approved and its efficacy and safety is being evaluated. Additional analyses will also be presented from the ANHELTO studies of Spiriva HandiHaler and olodaterol Respimat versus Spiriva HandiHaler alone, as well as the WISDOM trial evaluating the stepwise withdrawal of inhaled corticosteroids (ICS) in COPD. Also being presented are further analyses from the TIOSPIR trial comparing Spiriva Respimat and Spiriva HandiHaler.